Home › Study Describes Design, Validation of Foundation Medicine's Blood-Based TMB Test

Study Describes Design, Validation of Foundation Medicine's Blood-Based TMB Test

Aug 06, 2018

NEW YORK (GenomeWeb) – Researchers from Genentech, Foundation Medicine, UC Davis, and other medical centers, have published a report on the development and early validation of Foundation's planned blood-based tumor mutational burden test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Cancer

  1. Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

  2. Digital Pathology Startup Deep Lens Emerges From Stealth Mode

  3. DiaCarta Lands $2M SBIR Grant to Develop Radiation Toxicity Assay

  4. AmoyDx Lung Cancer CDx Approved in South Korea

  5. NCCN Update on Breast Cancer Genetic Testing Guidelines Marks Oncotype DX as 'Preferred' Test

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.